NLRP3 and melanoma: The percentage of MDSCs in melanoma, thymoma, and breast cancer in mice was decreased with NLRP3 deletion, but gemcitabine and 5-FU showed significantly increased antitumour efficacy [33,43] and significantly prolonged survival.